https://assets.capyfin.com/instruments/678fdc13234e27009c5d5fc5.png avatar
Evolent Health
🇺🇸 NYSE:EVH
View Company
OverviewEarningsDividends
•
Dec 31, 2020

Evolent Health Q4 2020 Earnings Report

Evolent Health reported a revenue increase of 15.0% year-over-year, achieved adjusted EBITDA of $16.1 million, and experienced a net loss attributable to common shareholders of $(14.6) million.

Key Takeaways

Evolent Health announced its Q4 and full-year 2020 results, revealing a 15.0% increase in GAAP revenue to $271.9 million for the quarter. The company achieved an adjusted EBITDA of $16.1 million, but reported a net loss attributable to common shareholders of $(14.6) million. Evolent also added new regional physician group partners and expanded its partnership with Blue Cross Blue Shield of Texas.

GAAP revenue increased by 15.0% year-over-year to $271.9 million.

Net loss attributable to common shareholders was $(14.6) million.

Adjusted EBITDA reached $16.1 million.

Lives on Full Platform of approximately 3.6 million and New Century Health Technology & Services Suite of 6.2 million

Total Revenue
$272M
Previous year: $238M
+14.5%
EPS
-$0.01
Previous year: -$0.07
-85.7%
Gross Profit
$95.2M
Previous year: $81.1M
+17.4%
Cash and Equivalents
$340M
Previous year: $101M
+237.1%
Total Assets
$1.37B
Previous year: $1.5B
-8.5%

Evolent Health

Evolent Health

Evolent Health Revenue by Segment

Forward Guidance

The Company is providing forward-looking guidance for the Services business only. Revenue for the year ending December 31, 2021 is expected to be in the range of approximately $830.0 million to $880.0 million. Adjusted EBITDA is expected to be in the range of approximately $40.0 million to $50.0 million.

Positive Outlook

  • Revenue for the year ending December 31, 2021 is expected to be in the range of approximately $830.0 million to $880.0 million.
  • Adjusted EBITDA is expected to be in the range of approximately $40.0 million to $50.0 million.
  • For the three months ending March 31, 2021, revenue is expected to be in the range of approximately $205.0 million to $215.0 million.
  • Adjusted EBITDA is expected to be in the range of approximately $10.0 million to $14.0 million.
  • Company to report True Health results as a discontinued operation in 2021

Challenges Ahead

  • Actual results may differ materially.
  • Factors that may cause actual results to differ materially from our current expectations are set forth below in "Forward Looking Statements - Cautionary Language" and Evolent Health, Inc.'s filings with the Securities and Exchange Commission ("SEC").
  • The pending sale of True Health New Mexico
  • Uncertainty in the health care regulatory framework, including the potential impact of policy changes
  • Evolution in the market for value-based care

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Company Overview

Full financial data and analysis

View Evolent Health